New gene therapy CTx1000 enters human safety trial for ALS
NCT ID NCT07401121
First seen Feb 12, 2026 · Last updated May 24, 2026 · Updated 14 times
Summary
This early-stage study tests a single dose of the gene therapy CTx1000 in 15 people with ALS. The main goal is to see if it is safe and tolerable. Participants must have been diagnosed within the last 2 years and be on stable standard medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Macquarie University Hospital
RECRUITINGSydney, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.